Compared with the overall cohort, patients prescribed GLP-1RA or SGLT2i were younger (mean age: GLP-1 RA: 61.1 years; SGLT2i: 63.0 years; overall: 66.3 years), had lower prevalence of heart failure (GLP-1 RA: 26.4%; SGLT2i: 21.4%; overall: 32.3%), had higher prevalence of dyslipidemia (GLP-1 RA: 87.2%; SGLT2i: 86.8%; overall: 81.5%), had fewer medical comorbidities (mean Charlson comorbidity index score: GLP-1 RA: 3.8; SGLT2i: 3.7; overall: 4.0) and had a lower percentage of patients with HbA1c < 7% (GLP-1 RA: 33.5%; SGLT2i: 36.6%; overall: 41.1%). The gene discussed is GLP1R; the disease is heart failure.